Fingerprint
Dive into the research topics of 'Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy
O. Stüve, P. D. Cravens, E. M. Frohman, J. T. Phillips, G. M. Remington, G. Von Geldern, S. Cepok, M. P. Singh, J. W. Cohen Tervaert, M. De Baets, D. MacManus, D. H. Miller, E. W. Radü, E. M. Cameron, N. L. Monson, S. Zhang, R. Kim, B. Hemmer, M. K. Racke
- VA North Texas Health Care System
- University of Texas Southwestern Medical Center
- UT Southwestern Medical Center
- Heinrich-Heine-University
- Multiple Sclerosis Center at Texas Neurology
- Maastricht University Medical Center
- University College London
- University Hospital Basel
- Neurology Research
- The Ohio State University Wexner Medical Center
Research output: Contribution to journal › Article › peer-review
115
Scopus
citations